NASDAQ: GPCR - Structure Therapeutics Inc.

半年間の収益性: -25.02%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Structure Therapeutics Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

さらに詳しく
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2023-02-03
ISIN US86366E1064
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://structuretx.com
Цена ао 41.15
1日あたりの価格変動: -1.69% (29.54)
週ごとの価格変動: +4.09% (27.9)
月ごとの料金変更: -13.96% (33.75)
3ヶ月間の価格変動: -30.44% (41.75)
半年間の価格変動: -25.02% (38.73)
年間の価格変動: -28.75% (40.76)
3年間の価格推移: 0% (29.04)
5年間の価格推移: 0% (29.04)
10年間の価格推移: 0% (29.04)
年初からの価格変動: -21.45% (36.97)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
合計: 2.75

効率

名前 意味 学年
ROA, % -18.58 0
ROE, % -19.77 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0536 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 642243.75 10
収益性 EPS, % 384724.96 10
合計: 8
さらに詳しく

機関 音量 共有, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETF 共有, % 年間の利益率, % 配当金, %
Future Tech ETF 0.24233 426.34 0.8416
Principal Healthcare Innovators ETF 0.24233 618.5 0.8416



スーパーバイザー 役職 支払い 生年
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (61 年)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (51 年)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (47 年)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (51 年)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

住所: United States, South San Francisco. CA, 611 Gateway Boulevard - Googleマップで開く, Yandexマップを開く
Webサイト: https://structuretx.com